Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong
· Delayed Price · Currency is HKD 31.98
+2.64 (9.00%)
Apr 29, 2026, 4:08 PM HKT
HKG:3378 Statistics
Total Valuation
HKG:3378 has a market cap or net worth of HKD 4.36 billion. The enterprise value is 3.75 billion.
| Market Cap | 4.36B |
| Enterprise Value | 3.75B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:3378 has 136.22 million shares outstanding.
| Current Share Class | 136.22M |
| Shares Outstanding | 136.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.43% |
| Owned by Institutions (%) | 2.32% |
| Float | 19.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 42,550.51 |
| PB Ratio | 5.24 |
| P/TBV Ratio | 5.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.71 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.27, with a Debt / Equity ratio of 0.07.
| Current Ratio | 7.27 |
| Quick Ratio | 6.86 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.50 |
Financial Efficiency
Return on equity (ROE) is -27.27% and return on invested capital (ROIC) is -17.58%.
| Return on Equity (ROE) | -27.27% |
| Return on Assets (ROA) | -12.63% |
| Return on Invested Capital (ROIC) | -17.58% |
| Return on Capital Employed (ROCE) | -17.27% |
| Weighted Average Cost of Capital (WACC) | 8.95% |
| Revenue Per Employee | 1,861 |
| Profits Per Employee | -2.65M |
| Employee Count | 55 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -15.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.84 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 24.33 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 63.18 |
| Average Volume (20 Days) | 131,885 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:3378 had revenue of HKD 102,379 and -145.79 million in losses. Loss per share was -1.24.
| Revenue | 102,379 |
| Gross Profit | 102,379 |
| Operating Income | -161.52M |
| Pretax Income | -161.40M |
| Net Income | -145.79M |
| EBITDA | -159.27M |
| EBIT | -161.52M |
| Loss Per Share | -1.24 |
Balance Sheet
The company has 725.74 million in cash and 62.16 million in debt, giving a net cash position of 663.57 million or 4.87 per share.
| Cash & Cash Equivalents | 725.74M |
| Total Debt | 62.16M |
| Net Cash | 663.57M |
| Net Cash Per Share | 4.87 |
| Equity (Book Value) | 831.96M |
| Book Value Per Share | 57.00 |
| Working Capital | 664.03M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.31M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -157,763.43% |
| Pretax Margin | -157,647.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:3378 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.35% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |